Patients with malignant melanoma who develop metastases during the first two years after diagnosis have significantly lower levels of tumor nm23-H1 expression (56% of the mean value) compared to patients with less aggressive disease (164%) [32]. The gene discussed is NME1; the disease is neoplasm.